WuXi Biologics Secures ISO 13485 Certification, Expanding Combination Product Capabilities

Event summary

  • WuXi Biologics achieved ISO 13485:2016 certification for medical device quality management systems with zero non-conformities.
  • The company is among the first in China's drug-device combination products sector to obtain this certification.
  • The certification validates WuXi Biologics' ability to handle both pharmaceutical and medical device regulatory requirements.
  • As of December 31, 2025, WuXi Biologics supports 945 integrated client projects, with complex modalities representing over half of the portfolio.

The big picture

The ISO 13485 certification signals WuXi Biologics' strategic move to expand its capabilities in the rapidly growing drug-device combination products market. This sector, blending pharmaceutical and medical device innovation, is attracting significant investment and presents a lucrative opportunity for CRDMOs with the requisite expertise. The certification validates WuXi Biologics’ commitment to meeting the stringent regulatory requirements of this complex area, positioning them to capture a larger share of the global market.

What we're watching

Regulatory Scrutiny
Increased adoption of combination products will likely draw greater regulatory attention, requiring WuXi Biologics to maintain rigorous compliance standards and potentially face evolving guidelines.
Competitive Landscape
This certification provides a competitive advantage, but other CRDMOs will likely pursue similar certifications, intensifying competition within the drug-device combination product space.
Integration Risk
Successfully integrating pharmaceutical and medical device processes requires ongoing coordination and expertise; any breakdown in this integration could impact service quality and client satisfaction.

Related topics

Medical Devices